Skip to content
PeptideAgent

Peptides for acromegaly: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Somatostatin analog peptides, octreotide and lanreotide, are the standard FDA approved medical treatment for acromegaly, normalizing growth hormone and IGF-1 in roughly half of patients in pooled data. Surgery to remove the pituitary tumor is first line. Growth hormone releasing research peptides raise growth hormone and have no role here.

Evidence: Strongest: Human RCT evidence2 peptides gradedVerified: Verified Sep 23, 2026

Do peptides help with acromegaly?

2 peptides are graded for acromegaly on this page. The strongest grade is human RCT evidence, for octreotide and lanreotide. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for acromegaly?

Transsphenoidal surgery by an experienced pituitary surgeon first line; somatostatin receptor ligands (octreotide, lanreotide, pasireotide) for persistent disease or when surgery is not possible; pegvisomant or cabergoline as alternatives or add ons; radiation for refractory disease; screen for diabetes, hypertension, sleep apnea, and colon polyps.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for acromegaly?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Acromegaly with evidence grades
PeptideEvidence for this useNote
OctreotideEvidence: Human RCT evidenceFDA approved for acromegaly as a daily injection, a monthly LAR depot, and oral capsules; gallstones and gastrointestinal effects are common. [2] [3] [4]
LanreotideEvidence: Human RCT evidenceNormalized growth hormone in about 48% and IGF-1 in about 47% of patients in a meta-analysis; FDA approved as Somatuline Depot. [2] [5]

Head-to-head comparisons

Frequently asked questions

Which peptide has the strongest evidence for acromegaly?

Octreotide and lanreotide have the strongest evidence among the peptides graded here, at human RCT evidence. Octreotide: FDA approved for acromegaly as a daily injection, a monthly LAR depot, and oral capsules; gallstones and gastrointestinal effects are common. Lanreotide: Normalized growth hormone in about 48% and IGF-1 in about 47% of patients in a meta-analysis; FDA approved as Somatuline Depot. [2] [3] [4] [5]

Is any peptide FDA approved for acromegaly?

Octreotide and lanreotide are FDA approved drugs, but an approval covers only the indications on that label, so check the label before assuming it applies to acromegaly. [2] [3] [4] [5] [6]

Has any peptide been tested in a randomized trial for acromegaly?

Yes, for octreotide and lanreotide. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [2] [3] [4] [5]

Sources

  1. [1]Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014PubMed 25356808, 2014
  2. [2]Long-acting somatostatin analog therapy of acromegaly: a meta-analysisPubMed 15886238, 2005
  3. [3]OctreotidePubMed 8532003, 1996
  4. [4]FDA prescribing information for Sandostatin and Sandostatin LAR (octreotide acetate), via DailyMedFDA, 2024
  5. [5]FDA prescribing information for Somatuline Depot (lanreotide) injection, via DailyMedFDA, 2024
  6. [6]Drugs@FDA: FDA-approved drugs databaseFDA